JAK2 and acquired polycythemia vera: As for the relationship between the prognosis and JAK2 mutations, no significant differences between JAK2V617F-mutated and JAK2 exon 12-mutated patients with PV have been observed [22]; nevertheless, JAK2V617F is a well-known risk factor of thrombosis [23,24].